In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Vibeke Backer discusses how Type 2 inflammation drives severe, uncontrolled CRSwNP. It covers key immune cells and biomarkers (e.g., IL-4, IL-5, IL-13, TSLP), global prevalence differences, and the importance of symptom tracking and targeted therapies.
Join ADVENT for an educational symposium on PN at WCI 2025!

This video clip from the EAACI 2024 symposium discusses whether patients with CRSwNP should undergo a surgery.

This video clip from the EAACI 2024 symposium highlights that a multidisciplinary approach is essential for the treatment of asthma.
In this ADVENT symposium at the 2024 EADV meeting, Professor Joost Meijer highlights the heterogeneous nature of BP and the resultant burden for patients.
In this ADVENT symposium at the 2024 EADV meeting, Professor Enno Schmidt discusses the pathophysiology of BP, focusing on autoimmunity and the role of type 2 inflammation.
In this ADVENT symposium at the 2024 EADV meeting, Dr. Donna Culton focuses on the challenges of diagnosis and the unmet needs for patients with BP.

Join Profs. Brian Lipworth, Zuzana Diamant, and Philippe Gevaert at an sponsored symposium about the latest strategies for the management of co-existing type 2 asthma and severe and/or uncontrolled CRSwNP.
This symposium highlights type 2 inflammation as a key driver of chronic itch and the characteristic skin lesions of prurigo nodularis and evaluates the real-world implications of targeted therapies on clinical practice.

Join experts Vibeke Backer, MD, DMSC, and Sietze Reitsma, MD, at an educational symposium involving a comprehensive exploration of the type 2 inflammation and its pivotal role in the pathogenesis and management of CRSwNP.

Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.
Join experts Jonathan Spergel, MD, PhD, Wanda Phipatanakul, MD, MS, and Jerry Ellen Schonfeld, CPNP, at an educational symposium as they investigate the role of type 2 inflammation in pediatric diseases. The speakers will also discuss the difficulties in diagnosis and burdens patients and their families face.